Sjogren syndrome

Last updated: July 22, 2021

Sjogren syndrome

MOD1

MOD1

T-cell development
T-cell activation
Antibody classes
Cell-mediated immunity of natural killer and CD8 cells
B- and T-cell memory
B-cell activation, differentiation, and contraction
B-cell development
Inflammation
Wound healing
VDJ rearrangement
Somatic hypermutation and affinity maturation
MHC class I and MHC class II molecules
Cell-mediated immunity of CD4 cells
Introduction to the immune system
Complement system
Metaplasia and dysplasia
Necrosis and apoptosis
Contracting the immune response and peripheral tolerance
Innate immune system
Abscesses
Hyperplasia and hypertrophy
Atrophy, aplasia, and hypoplasia
Bacterial structure and functions
Viral structure and functions
Candida
Polymerase chain reaction (PCR) and reverse-transcriptase PCR (RT-PCR)
ELISA (Enzyme-linked immunosorbent assay)
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Mechanisms of antibiotic resistance
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
COVID-19 mutant variants and herd immunity
Development of the COVID-19 vaccine
Dr. Tom Frieden: Former Director of the CDC (Raise the Line)
Incidence and prevalence
Prevention
Vaccinations: Clinical
COVID-19 vaccine hesitancy
Flatten the curve, raise the line music video
DALY and QALY
Hand hygiene (for nursing assistant training)
Types of personal protective equipment (for nursing assistant training)
Standard and transmission-based precautions (for nursing assistant training)
Type III hypersensitivity
Type IV hypersensitivity
Type I hypersensitivity
Type II hypersensitivity
Non-steroidal anti-inflammatory drugs
Lupus nephritis
IgA nephropathy (NORD)
Myasthenia gravis
Membranous nephropathy
Rheumatoid arthritis
Vasculitis
Vasculitis: Pathology review
Systemic lupus erythematosus (SLE): Clinical
Renal system anatomy and physiology
Kidney histology
Rapidly progressive glomerulonephritis
Sjogren syndrome
Graves disease
Bullous pemphigoid
Asthma
Systemic lupus erythematosus
Goodpasture syndrome
Acetaminophen (Paracetamol)
Glucocorticoids
Complement deficiency
Atopic dermatitis
Erythema multiforme
Non-corticosteroid immunosuppressants and immunotherapies
BK virus (Hemorrhagic cystitis)
Transplant rejection

Transcript

Watch video only

Sjogren's syndrome, named after Dr. Henrik Sjogren who first identified it, is a common autoimmune disorder, typically occurring in women.

In Sjogren’s syndrome, the body’s immune cells go rogue and start attacking various exocrine glands, which are glands that pour their secretions into a duct; most commonly the salivary glands and the lacrimal, or tear, glands.

Normally, the cells of the immune system are ready to spot and destroy anything foreign pathogens that could cause the body harm.

Immune cells called antigen-presenting cells, which include macrophages and dendritic cells, latch onto pathogens and engulf them - literally swallowing them up.

Pieces of the pathogen called antigens are then presented on a major histocompatibility complex class II molecule, or MHC-class II molecule - which is like a serving platter for antigens. An antigen presenting cell then searches for a T cell that can bind to the antigen.

Once found, binding to the antigen helps activate this T cell, which then releases proinflammatory cytokines, or signaling molecules, that recruit more immune cells - ultimately leading to inflammation.

The exact cause for Sjogren's syndrome is unknown, but it seems to be related to both genetic and environmental factors.

Genetic factors include genes which code for specific types of MHC class II molecules, called human leukocyte antigen, or HLA genes. Specifically HLA- DRW52, HLA- DQA1, or HLA- DQB1.

Environmental factors include an infection of exocrine glands like the salivary and lacrimal glands. Infections can damage the cells of the salivary gland, and expose their cell components, including their DNA, RNA, and histones to circulating immune cells.

These cell components get picked up by antigen-presenting cells, and presented to T-cells. In individuals with Sjogren's syndrome, a T cell gets inappropriately activated by these nuclear components, and considers them to be foreign nuclear antigens.

The T-cells then activate B-cells, which start producing anti-nuclear antibodies, or ANAs, which are antibodies against the nuclear antigens.

Two types of ANA formed in Sjogren’s syndrome are anti- SS-A and anti- SS-B antibodies, which are formed against the ribonucleoproteins SS-A and SS-B.

Then, both T-cells and antibodies enter the circulation and reach the exocrine glands, where the T-cells secrete cytokines to recruit more immune cells and promote inflammation of the exocrine gland tissue.

Key Takeaways

Sjogren's syndrome is an autoimmune disease in which the body's immune cells attack various moisture-producing exocrine glands, which normally pour their secretions into various ducts in the body, such as the salivary and the lacrimal glands. This results in the development of a dry mouth and dry eyes. Other symptoms can include dry skin, a chronic cough, vaginal dryness, numbness in the arms and legs, feeling tired, and muscle and joint pains. Treatment of Sjogren's syndrome typically involves medications to suppress the immune response, like corticosteroids; and also medications that increase the exocrine secretions like pilocarpine.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Update in Sjögren syndrome" Current Opinion in Rheumatology (2000)
  6. "Novel autoantibodies in Sjögren's syndrome: A comprehensive review" Autoimmunity Reviews (2019)
  7. "Sjögren's syndrome" The Lancet (2005)